Tranexamic acid for the prevention of postpartum hemorrhage and decreasing blood loss after vaginal delivery in high-risky parturient: A double-blind randomized controlled trial

Chro Sharef Hasan; Shahla Kareem Alalaf; Sazgar Abdulla Khoshnaw

doi:10.15218/zjms.2022.024

Authors

Chro Sharef Hasan Department of Obstetrics and Gynecology, Maternity Teaching Hospital, Directorate of Health, Erbil, Iraq
Shahla Kareem Alalaf Department of Obstetrics and Gynecology, College of Medicine, Hawler Medical University, Erbil, Iraq
Sazgar Abdulla Khoshnaw Department of Obstetrics and Gynecology, Maternity Teaching Hospital, Directorate of Health, Erbil, Iraq

DOI:

https://doi.org/10.15218/zjms.2022.024

Keywords:

High-risk pregnancy, Oxytocin, Postpartum hemorrhage, Third stage labor, Tranexamic acid

Abstract

Background and objective: The purpose of this study was to examine the effectiveness of Tranexamic acid administered in the third stage of labor to reduce vaginal blood loss and prevent postpartum hemorrhage in women with high-risk factors for postpartum Hemorrhage.

Methods: A double-blind randomized placebo-controlled trial with two parallel groups was conducted in women scheduled to undergo vaginal delivery at the Maternity Teaching Hospital, Erbil city, Kurdistan Region, Iraq. The women were randomly assigned to receive tranexamic acid (97 women) or placebo (99 women) immediately after fetal delivery in the third stage of labor. The vaginal blood loss and the time from fetal to placental delivery were measured.

Results: The mean blood loss in the placebo group (Group 1) was 354.5 gram, which was considerably greater than the mean blood loss in the tranexamic group (Group 2), which was 284.4 gram. The incidence of postpartum hemorrhage (blood loss of ≥500 ml.) and (blood loss of ≥250 ml.) was significantly higher in G1 than G2. The length of the third stage of labor lasted 10.28 minutes in G1, which was longer than in G2, which lasted 7.82 minutes. Oxytocin was given to both groups as an active management of the third stage of labor.

Conclusion: In this single-center study, women with risk factors for postpartum hemorrhage who received tranexamic acid had lower postpartum blood loss and a shorter time for placental delivery than those women who received placebo. Larger multicenter randomized clinical trials are needed to generalize these findings.

Metrics

Metrics Loading ...

References

Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, et al. Global causes of maternal death: A WHO systematic analysis. Lancet Glob Heal. 2014; 2(6):323–33.

Ononge S, Mirembe F, Wandabwa J, Campbell OMR. Incidence and risk factors for postpartum hemorrhage in Uganda. Reprod Health. 2016; 13(1):1–7. http://doi.org/10.1186/s12978-016-0154-8

Calvert C, Thomas SL, Ronsmans C, Wagner KS, Adler AJ, Filippi V. Identifying regional variation in the prevalence of postpartum haemorrhage: A systematic review and meta-analysis. PLoS One. 2012; 7(7):e41114.

Kramer MS, Berg C, Abenhaim H, Dahhou M, Rouleau J, Mehrabadi A, et al. Incidence, risk factors, and temporal trends in severe postpartum hemorrhage. Am J Obstet Gynecol. 2013; 209(5):449.e1–7. http://doi.org/10.1016/j.ajog.2013.07.007

WHO. Active management of the third stage of labour. Vol. 6736. 2013. https://www.who.int/reproductivehealth/publications/maternal_perinatal_health/new-recommendations-amtsl/en

Nyfløt LT, Sandven I, Stray-Pedersen B, Pettersen S, Al-Zirqi I, Rosenberg M, et al. Risk factors for severe postpartum hemorrhage: A case-control study. BMC Pregnancy Childbirth. 2017; 17(1):1–9. http://doi.org/10.1186/s12884-016-1217-0

Mccormack PL. Tranexamic Acid A Review of its Use in the Treatment of Hyperfibrinolysis. ADIS DRUG Eval. 2012; 72(5):585–617.

Franchini M, Mengoli C, Cruciani M, Bergamini V, Presti F, Marano G, et al. Safety and efficacy of tranexamic acid for prevention of obstetric haemorrhage: An updated systematic review and meta-analysis. Blood Transfus. 2018; 16(4):329–37.

Shakur H, Roberts I, Fawole B, Chaudhri R, El-Sheikh M, Akintan A, et al. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017; 389(10084):2105–16.

Novikova N, Hofmeyr GJ, Cluver C. Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2015; 2015(6):1–62.

Calkins LA. Management of the third stage of labor. J Am Med Assoc.1933; 101(15):1128–31.

Edwards HM. Aetiology and treatment of severe postpartum haemorrhage. Dan Med J. 2018; 65(3):1–20.

Li C, Gong Y, Dong L, Xie B, Dai Z. Is prophylactic tranexamic acid administration effective and safe for postpartum hemorrhage prevention? A systematic review and meta-analysis. Med (United States). 2017; 96(1):1–11.

Gungorduk K, Ascoǧlu O, Yldrm G, Ark C, Tekirdaǧ AI, Besmoglu B. Can intravenous injection of tranexamic acid be used in routine practice with active management of the third stage of labor in vaginal delivery? A randomized controlled study. Obstet Gynecol Surv. 2013; 68(10):673–5.

Mirghafourv M, Mohammad-Alizadeh S, Abbasalizadeh F, Shirdel M. The effect of prophylactic intravenous tranexamic acid on blood loss after vaginal delivery in women at low risk of postpartum haemorrhage: A double-blind randomised controlled trial. Aust New Zeal J Obstet Gynaecol. 2015; 55(1):53–8.

Sentilhes L, Winer N, Azria E, Sénat M-V, Le Ray C, Vardon D, et al. Tranexamic Acid for the Prevention of Blood Loss after Vaginal Delivery. N Engl J Med. 2018; 379(8):731–42.

Muniro Z, Tarimo CS, Mahande MJ, Maro E, McHome B. Grand multiparity as a predictor of adverse pregnancy outcome among women who delivered at a tertiary hospital in Northern Tanzania. BMC Pregnancy Childbirth. 2019; 19(1).

Jackson R, States U. Macrosomia: ACOG Practice Bulletin, Number 216. Obstet Gynecol. 2020; 135(1):E18–35.

Walker KF, Wilson P, Bugg GJ, Dencker A, Thornton JG. Childbirth experience questionnaire: Validating its use in the United Kingdom. BMC Pregnancy Childbirth. 2015; 15(1):1–8.

Gai MY, Wu LF, Su QF, Tatsumoto K. Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: A multi-center, randomized trial. Eur J Obstet Gynecol Reprod Biol. 2004; 112(2):154–7.

Anderson JM, Etches D. Prevention and management of postpartum hemorrhage. Am Fam Physician. 2007; 75(6):875–82.

Sentilhes L, Vayssière C, Deneux-Tharaux C, Aya AG, Bayoumeu F, Bonnet MP, et al. Postpartum hemorrhage: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF) in collaboration with the French Society of Anesthesiology and Intensive Care (SFAR). Eur J Obstet Gynecol Reprod Biol. 2016; 198:12–21.

Hawker L, Weeks A. Postpartum haemorrhage (PPH) rates in randomized trials of PPH prophylactic interventions and the effect of underlying participant PPH risk: A meta-analysis. BMC Pregnancy Childbirth. 2020; 20(1):1–12.

Diab K M, Mohamed R M, Abdelhay AG. The Efficacy of Intravenous Tranexamic Acid in Reduction of Blood Loss in Women at High Risk of Postpartum Hemorrhage. An Int J Medicine. 2020; 113(1):2020.

Borders AE. Quantitative Blood Loss in Obstetric Hemorrhage: ACOG COMMITTEE OPINION SUMMARY, Number 794. Obstet Gynecol. 2019; 134(6):1368–9.